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Background: Intraperitoneal (IP) chemotherapy is garnering attention as an effective treatment for gastric cancer
with peritoneal metastasis. We report the case of a patient who developed colonic stenosis caused by infection of
an IP access port system during IP chemotherapy. It was difficult to differentiate whether the extrinsic colonic
stenosis arose from a catheter infection or peritoneal metastasis of the gastric cancer.
Case presentation: A 66-year-old Japanese man underwent total gastrectomy for gastric cancer. Because the
intraoperative findings revealed peritoneal metastasis, a port system was implanted for subsequent IP chemotherapy.
Two months after initiation of chemotherapy, he complained of vomiting and abdominal pain. A computed
tomography scan revealed marked thickening of the sigmoid colon wall adjacent to the catheter of the IP access port
system. A barium enema demonstrated extrinsic irregular stenosis of the sigmoid colon. Although it was difficult to
distinguish whether infection or peritoneal metastasis had caused the colonic stenosis, we removed the port system to
obtain a therapeutic diagnosis. Coagulase-negative staphylococci were detected by catheter culture. The wall
thickening and stenosis of the sigmoid colon completely resolved after removal of the port system.
Conclusions: We report the case of a rare complication in association with an IP access port system. Infection of the
port system should be considered as a differential diagnosis when colonic stenosis adjacent to the catheter is observed
during IP chemotherapy.
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Gastric cancer is a major cause of cancer death world-
wide. Recent advances in systemic chemotherapy regi-
mens have shown encouraging tumor response rates and
increased survival in patients with unresectable or meta-
static gastric cancer [1]. However, treatment outcomes
for patients with peritoneal metastasis, which is the most
frequent metastatic pattern of recurrence, have not im-
proved sufficiently [2].* Correspondence: junkino0416@gmail.com
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unless otherwise stated.Intraperitoneal (IP) chemotherapy is garnering atten-
tion as an effective treatment for peritoneal metasta-
sis because of the theoretical advantage of higher local
concentrations, prolonged tumor exposure, and reduced
systemic toxicity [3,4]. IP chemotherapy was shown to
prolong survival in a phase III study of ovarian cancer
with peritoneal metastasis and has been approved as a
recommended regimen by the National Cancer Institute
in the United States [5]. IP chemotherapy has also been
shown to be a promising treatment option for gastric
cancer [6-9]. A multicenter randomized clinical trial is
now ongoing to generate evidence regarding the effectsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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metastasis.
A subcutaneous port and catheter system has been de-
veloped and is now the most common route through
which chemotherapeutic agents are administered into
the peritoneal cavity. The main advantages of subcutane-
ous systems are the low rate of port-related infections
and the ease of drug administration into the peritoneal
cavity [10]. However, complications associated with sub-
cutaneous port systems have been reported in patients
with ovarian cancer and gastric cancer [10-19].
We herein describe a patient who developed colonic
stenosis caused by the infection of an IP access port sys-
tem during IP chemotherapy for gastric cancer with peri-
toneal metastasis. It was difficult to differentiate whether
the extrinsic colonic stenosis arose from a catheter infec-
tion or the peritoneal metastasis.Figure 1 Intraperitoneal access port system. The intraperitoneal
access port system comprised of a titanium port with a bottom
diameter of 31.47 mm, a height of 14.5 mm, and a 14.3-Fr single-
lumen silicone catheter.Case presentation
A 66-year-old Japanese male patient was discovered to
have anemia (hemoglobin level, 6.1 g/dL) at a medical
checkup. He underwent upper gastrointestinal endos-
copy, which revealed Borrmann’s type IV gastric cancer,
and the biopsy findings resulted in a diagnosis of mode-
rately differentiated adenocarcinoma. He then consulted
with our hospital for surgical treatment.
A detailed examination revealed T3N1M0 (stage IIB)
cancer according to the Union for International Cancer
Control tumor, node, and metastasis classification. Al-
though a laparotomy was performed for curative resec-
tion, serosal invasion of the primary tumor and multiple
peritoneal metastases in the peritoneal cavity were dis-
covered intraoperatively. Peritoneal lavage cytology was
also positive according to the Japanese classification of
gastric carcinoma. We performed a total gastrectomy for
cytoreduction and implanted an IP access port system
(Bardport-Ti; CR Bard Inc., New Jersey, United States)
comprising of a titanium port with a bottom diameter of
31.47 mm, a height of 14.5 mm, and a 14.3- Fr single-
lumen silicone catheter (Figure 1) for postoperative IP
chemotherapy. The subcutaneous space was dissected
and a pocket for implantation of the port was created in
the right lower abdomen. A catheter was then inserted
from the subcutaneous pocket into the peritoneal cavity,
penetrating the abdominal wall, and the end of the cath-
eter was placed in the pelvis.
The postoperative course was uneventful. On postop-
erative day 14 the patient began chemotherapy with S-1
(TS-1®; Taiho Pharmaceutical Company, Tokyo, Japan)
at 80 mg/m2/day (2 weeks on, 2 weeks off ) and doce-
taxel administered intraperitoneally at 45 mg/m2 (days 1
and 15). He was discharged on postoperative day 29 and
underwent outpatient chemotherapy.Two months after implantation of the IP access port
the patient developed vomiting and abdominal pain. An
abdominal X-ray showed dilatation of the small in-
testine. He was alert upon admission to department of
gastroenterologic surgery of our hospital, with a blood
pressure of 110/53 mmHg, a pulse rate of 64 beats/min,
and a body temperature of 36.8°C. A physical examin-
ation was performed and localized tenderness was seen
in the left lower abdomen apart from the port site. Nei-
ther port-site erythema nor swelling was observed. La-
boratory data showed normal leukocyte and neutrophil
counts (8420/μL and 4910/μL, respectively) and a slightly
elevated C-reactive protein level (3.6 mg/dL). He was
admitted with a diagnosis of ileus and a nasogastric tube
was inserted. However, the left lower abdominal pain
persisted.
Anabdominal computed tomography scan revealed
marked wall thickening and narrowing of the lumen
of the sigmoid colon adjacent to the catheter of the IP ac-
cess port system (Figure 2A). A barium enema also dem-
onstrated extrinsic irregular stenosis of the sigmoid colon
(Figure 3A). We initially suspected peritoneal metastasis
from gastric cancer and considered colostomy as a pallia-
tive operation. However, the stenosis was determined to
have resulted from inflammation due to catheter infection
because the intestinal stenosis was confined to the sig-
moid colon, which was not a common site of peritoneal
metastasis such as transverse-colon or rectum, and the
Figure 2 Computed tomographic changes in sigmoid colon
before and after removal of intraperitoneal access port system.
(A) A computed tomography scan showed marked wall thickening
of the sigmoid colon (closed triangle) adjacent to the catheter
(arrowhead) before removal. (B) Seven days after port removal,
the wall thickening of the sigmoid colon had improved
(open triangle).
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usual course of peritoneal metastasis. Therefore, we re-
moved the IP access port system under local anesthesia
for a therapeutic diagnosis and began cephalosporin ad-
ministration. At the time of port system removal, thereFigure 3 Extrinsic irregular stenosis of the sigmoid colon on barium e
sigmoid colon around the catheter (arrowheads). (B) Four months after rem
completely disappeared.was no abscess in the subcutaneous space and no fibrin
clots were occluding the lumen of the catheter.
However, after the port system removal the patient’s
abdominal pain immediately disappeared and he could
ingest food normally several days later. In addition, an
abdominal computed tomography scan demonstrated
improvement in the thickening of the sigmoid colon
wall seven days after port system removal (Figure 2B).
Coagulase-negative staphylococci were detected by ca-
theter culture. A colonofiberscopy showed no diverticula
in the sigmoid colon, and that the mucosa was intact.
Based on the patient’s clinical course and the above-
described findings, we conclusively attributed the colonic
stenosis to infection of the catheter. He was discharged
on the 21 days after admission. The stenosis of the sig-
moid colon had completely disappeared four months
after port system removal as shown by a barium enema
(Figure 3B).
Outpatient chemotherapy with S-1 and intravenous
docetaxel was performed. A re-laparoscopy was subse-
quently performed to evaluate the patient’s response to
chemotherapy. There were abnormal findings such as
fibrosis, scar formation, or macroscopic progression
of peritoneal metastasis in the sigmoid colon and its
mesentery.
An IP access port system was re-implanted four
months after removal. The patient remains alive with-
out progression of peritoneal metastasis six months
after surgery.Discussion
A well-established principle of IP chemotherapy is the
regional pharmacologic advantage achieved by direct in-
stillation of drugs into the peritoneal cavity. A recent
phase II study of intravenous and IP paclitaxel combinednema. (A) Barium enema showed extrinsic irregular stenosis of the
oval of the port system, the stenosis of the sigmoid colon had
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and a median survival time of 22.5 months for patients
with peritoneal metastasis from gastric cancer [6]. Other
clinical trials involving IP chemotherapy with taxane
agents have also shown favorable prognoses, with a
median survival time of 16.2 to 24.6 months [7-9]. A
multicenter randomized clinical trial is now ongoing
to generate evidence regarding the effects of IP chemo-
therapy on gastric cancer with peritoneal metastasis.
To date, several reports have investigated complica-
tions associated with implanted subcutaneous ports and
catheters for IP treatment of ovarian and gastric cancer
[10-19]. Infection and malfunction were the most com-
mon complications; the rate of infection was reportedly
2.1% to 10.7%, and the rate of malfunction was 3.7% to
18.2% (Table 1). Emoto et al. reported that intestinal
bacteria were found in bacterial cultures of lavage fluid
obtained through the port in six out of nine patients
[19]. Although a relationship appears to exist between
infection and gastrointestinal surgery performed con-
currently with port implantation, no evidence of this
relationship has been found in previous retrospective
studies. In our patient, we implanted subcutaneous ports
and catheters concurrently with total gastrectomy, but
the catheter culture revealed coagulase-negative staphy-
lococci. This suggests that the catheter infection was
due to contamination of the port site at the time of
needling or contamination via the infusion device be-
cause coagulase-negative staphylococci are the resident
bacteria of the skin. It is important for medical staff
members to take standard precautions to prevent port
infections as presented here.
Previous studies have reported that gut-associated com-
plications included fistula formation and perforation (0.0
to 3.5%). Braly et al. also reported one case of small bowel
obstruction due to an IP catheter [17]. Fibrous sheath for-
mation around the catheter was thought to pose a risk of
small bowel obstruction [20].Table 1 Complications associated with intraperitoneal access
Author Year *n Type of
cancer
Malfunction Infect
*n (%) *n (%
Pfeifle et al. [18] 1984 54 ovarian cancer 3 (5.5) 3 (5.
Piccart et al. [12] 1985 145 ovarian cancer 3 (2.1) 12 (8
Braly et al. [17] 1986 33 ovarian cancer 2 (6.1) 6 (18
Davidson et al. [13] 1991 227 ovarian cancer 20 (8.8) 12 (5
Malmastorm et al. [14] 1994 125 ovarian cancer 6 (4.8) 5 (4.
Topuz et al. [10] 2000 56 ovarian cancer 6 (10.7) 3 (5.
Makhija et al. [15] 2001 301 ovarian cancer 19 (6.3) 11 (3
Walker et al. [16] 2006 205 ovarian cancer 18 (8.8) 21 (1
Emoto et al. [19] 2012 131 gastric cancer 10 (7.6) 9 (6.To the best of our knowledge this is the first case of
colonic stenosis as a complication of an IP port. We
could not clarify the mechanism of the stenosis of the
sigmoid colon in this case. We speculate that inflamma-
tion secondary to the catheter infection was the main
contributor to the wall thickening and subsequent sten-
osis of the sigmoid colon because we did not observe
numerous fibrous sheaths attached to the catheter at the
time of removal. An important point of our case is that
the extrinsic stenosis was remarkably similar in appear-
ance to peritoneal metastasis. In general, peritoneal me-
tastasis from gastric cancer frequently involves stenosis
of the colorectum. In this case, the gut stenosis was not
histologically confirmed by colonofiberscopy because it
extended from the serosal side of the colonic wall. The
findings obtained by barium enema were characteristic
of the metastatic carcinoma that extended from the se-
rosal side of the colonic wall.
Our patient had no fever and no severe acute inflam-
matory changes were found upon blood examination du-
ring the infectious episode. Therefore, it was difficult to
distinguish whether infection or peritoneal metastasis
caused the colonic stenosis. Such a diagnosis should be
cautiously obtained because it substantially influences
the subsequent treatment plan.
The occurrence of port complications in gastric cancer
has been investigated in only one other report [19] ac-
cording to our review of the literature, and has not been
fully eliminated as is the case in ovarian cancer. Because
peritoneal metastasis of gastric cancer more frequently
involves enterostenosis than peritoneal metastasis of ovar-
ian cancer, our case is thought to be significant in terms of
the management of IP chemotherapy-induced complica-
tions, especially in patients with gastric cancer.
Conclusions
In summary, we report the case of a rare complication
in association with an IP access port system. Infection ofport systems in previous reports *n: number of patient
ion Bowel perforation/fistula Small bowel obstruction Total
) *n (%) *n (%) *n (%)
5) 0 0 6(11)
.3) 2 (1.4) 0 17 (11.7)
.2) 1 (3.0) 1 (3.0) 10 (30.3)
.3) 8 (3.5) 0 40 (17.6)
0) 0 0 37 (30)
4) 1 (1.8) 0 10 (18)
.7) 0 0 30 (10)
0) 4 (2.0) 0 40 (20)
9) 2 (1.5) 0 27 (21)
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diagnosis when colonic stenosis adjacent to the catheter
is observed during IP chemotherapy.
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